Nasdaq · CIK 0001927719
CRGO Freightos Ltd
Insider trading from SEC Form 4. Last filing 7 d ago. Close $0.84 on Oct 9, 2026, +3% from the 52-week low and -80% from the high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Freightos Ltd, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Manrique de Lara Pablo Pinillos CEO sell | $1,366 1,535 shares | -5% | - | |
| 15Weak | Ian Arroyo Chief Strategy Officer sell | $1,935 1,217 shares | -5% | +33% from low-61% from high | |
| 15Weak | Abril Enric Alventosa Chief Technology Officer sell | $5,953 2,904 shares | -10% | +59% from low-53% from high | |
| 23Weak | Abril Enric Alventosa Chief Technology Officer sell | $4,656 2,517 shares | -8% | +59% from low-53% from high | |
| 33Weak | Ian Arroyo Chief Strategy Officer sell | $3,239 1,751 shares | -25% | +59% from low-53% from high | |
| 40Moderate | Manrique de Lara Pablo Pinillos CEO and CFO sell | $28k 17,898 shares | -43% | +36% from low-60% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 26, 2025 | Shalev Ran Officer | 16,671 0.03% of outstanding | $42k | Mar 25, 2025 | $5,799 |
| Nov 27, 2024 | Medrano Manuel Galindo Ex Officer | 367,800 0.77% of outstanding | $772k | Nov 27, 2024 | $31k |
| Nov 15, 2024 | Medrano Manuel Galindo Officer | 12,005 0.03% of outstanding | $26k | Nov 11, 2024 | $1,501 |
Transactions
The last 12 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Manrique de Lara Pablo Pinillos CEO | SOpen-market sale Ordinary Shares | -1,535 | $0.89 | $1,366 | 31,126 | 7 d ago |
| Sep 1, 2026 | Yaron Eldad Chief Financial Officer | AGrant or award Ordinary Shares | +40,000 | $0.00 | $0 | 40,000 | 26 d ago |
| Sep 1, 2026 | Yaron Eldad Chief Financial Officer | AGrant or award Ordinary Shares | +20,000 | $0.00 | $0 | 20,000 | 26 d ago |
| Sep 1, 2026 | Yaron Eldad Chief Financial Officer | AGrant or award Ordinary Shares | +20,000 | $0.00 | $0 | 20,000 | 26 d ago |
| Jun 15, 2026 | Ian Arroyo Chief Strategy Officer | SOpen-market sale Ordinary Shares | -1,217 | $1.59 | $1,935 | 23,924 | Jun 16, 2026 |
| Jun 10, 2026 | Ian Arroyo Chief Strategy Officer | AGrant or award Ordinary Shares | +4,000 | $0.00 | $0 | 25,141 | Jun 11, 2026 |
| May 28, 2026 | Abril Enric Alventosa Chief Technology Officer | SOpen-market sale Ordinary Shares | -2,904 | $2.05 | $5,953 | 26,746 | Jun 1, 2026 |
| Apr 16, 2026 | Abril Enric Alventosa Chief Technology Officer | SOpen-market sale Ordinary Shares | -1,170 | $1.85 | $2,165 | 29,650 | Apr 20, 2026 |
| Apr 16, 2026 | Ian Arroyo Chief Strategy Officer | SOpen-market sale Ordinary Shares | -756 | $1.85 | $1,399 | 6,244 | Apr 20, 2026 |
| Apr 16, 2026 | Abril Enric Alventosa Chief Technology Officer | SOpen-market sale Ordinary Shares | -1,347 | $1.85 | $2,492 | 34,133 | Apr 20, 2026 |
| Apr 16, 2026 | Ian Arroyo Chief Strategy Officer | SOpen-market sale Ordinary Shares | -995 | $1.85 | $1,841 | 20,505 | Apr 20, 2026 |
| Mar 31, 2026 | Manrique de Lara Pablo Pinillos CEO and CFO | SOpen-market sale Ordinary Shares | -17,898 | $1.57 | $28k | 24,102 | Mar 31, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Abril Enric AlventosaChief Technology Officer
- Ian ArroyoChief Strategy Officer
- Yaron EldadChief Financial Officer
- Manrique de Lara Pablo PinillosCEO and CFO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.